United States: The Silver Lining In The DEA's Refusal To Reclassify Cannabis

As far back as 2011, elected officials have sent letters to the U.S. Drug Enforcement Administration urging it to reclassify cannabis by removing it from the list of Schedule I controlled substances. After promising a response in the "second half of 2016," the DEA released a series of documents on Aug. 11, 2016 that refused to reclassify cannabis but opened doors to the development of cannabis-based products.

Underpinning the announcement was the clear message that until the FDA is presented with significant, clinical evidence of cannabis' effectiveness in treating diseases or conditions, supplied by approved drug trials, the DEA will not change the Schedule I status of cannabis. Although the decision was not the news the industry hoped for, it did open the door to real changes in the way that the cannabis industry can leverage medical applications of cannabis.

The DEA drug classification system

Pursuant to the authority in 21 U.S.C. §801 et seq, the DEA maintains a list of controlled substances, each of which are classed on a schedule with Schedule V being the group of drugs that require the least restrictive controls. There are a total of five different schedules. These schedules apply increasing levels of control and limitations on each substance listed thereon but in a descending order. For example, Schedule I drugs are those that have been found to have "no currently accepted medical use and a high potential for abuse. Schedule I drugs are the most dangerous drugs of all the drug schedules with potentially severe psychological or physical dependence." The schedule status of a drug is based on the available scientific data regarding the safety of the compound, the risk of abuse, and available medical benefit the substance provides. Cannabis, as a Schedule I drug, has therefore historically had, at the federal level, experienced the greatest number of limitations and controls.

With the emergence of the cannabis industry and its growth, there has been a true grassroots effort to deschedule cannabis. A wide group of advocates, including elected officials, have sent letters to the DEA asking that the current scheduling of cannabis be changed. One such official, Sen. Elizabeth Warren of Massachusetts, sent a letter, to the DEA emphasizing the importance of continued research with cannabis as further support to lift the Class I scheduling limitations. Specifically, the letter noted:

Currently, twenty-three states and the District of Columbia have passed laws allowing for medical marijuana use, and an additional fifteen states have laws specifically allowing access to cannabadiol (CBD). While the federal government has emphasized research on the potential harms associated with the use of marijuana, there is still very limited research on the potential health benefits of marijuana – despite the fact that millions of Americans are now eligible by state law to use the drug for medical purposes.

This language, among other statements in Sen. Warren's letter, was clearly echoed in the DEA's pronouncement.

The DEA's decision to not reclassify or deschedule cannabis

The DEA's decision not to change the Schedule I status of cannabis consisted of a letter from the DEA to the senators, as well as two filings ( 1 and 2) to the Federal Register. The letter makes clear that these decisions are focused on enabling the FDA to perform its function in ensuring that any new drugs are subjected to rigorous clinical testing and scientific analysis to ensure that any drug product available to U.S. consumers is safe and effective for its intended use. The DEA's letter raises the FDA's role moving forward, specifically:

The FDA drug approval process for evaluating potential medicines has worked effectively in this country for more than 50 years. It is a thorough, deliberate, and exacting process grounded in science, and properly so, because the safety of our citizens relies on it. Using established scientific standards that are consistent with that same FDA drug approval process and based on the FDA's scientific and medical evaluation, as well as the legal standards in the CSA, marijuana will remain a Schedule I controlled substance. It does not have a currently accepted medical use in treatment in the United States, there is a lack of accepted safety for its use under medical supervision, and it has a high potential for abuse.

As part of this review, the DEA obtained from the FDA an unpublished lengthy report on the status of cannabis science as it relates to human health. This review emphasized the standards by which a new drug can gain approval. This includes:

  • The drug's chemistry must be known and reproducible
  • There must be adequate safety studies
  • There must be adequate, well-controlled studies showing efficacy
  • The drug must be accepted by qualified experts
  • The scientific evidence for the safety and efficacy of the drug must be widely available

In recommending that cannabis not be descheduled, the FDA identified multiple known health issues related to cannabis use, including prenatal exposure, behavioral effects, deleterious impact on those prone to psychoses, and negative impacts on a patient's cardiovascular, endocrine, respiratory, and immune systems. In addition, given the inconsistent quality and limited amount of controlled cannabis research, and lack of NDAs or INDAs, the FDA concluded that the current evidence did not support the rescheduling of cannabis.

In essence, in its statement, the DEA adopted the FDA's opinion, stating that while the use of cannabis for treating a variety of conditions has seen approval at the state level, the federal government has yet to see sufficient scientific clinical evidence of safety and efficacy to warrant the reclassification of cannabis. The DEA's letter ends with the statement, "But we will remain tethered to science, as we must, and as the statute demands."

One door closes, another opens

While this is not the decision that the cannabis industry was looking for, when Sen. Warren's letter was first published, the letter and its attached materials outline current efforts by the DEA to enable research on cannabis and its components. For example, last year, the DEA waived certain regulatory requirements for researchers investigating cannibidiol (CBD). To date, all petitions from researchers under these changes have been granted.

Prior to the August decision of the DEA, only one institution, the University of Mississippi, had been granted a license for the cultivation of marijuana for research purposes. Until the DEA's recent announcement, researchers looking to obtain cannabis product for research could only go through this single NIDA source. The reasoning for this single license lies with a very dated international treaty. Under the 1961 International Single Convention on Narcotic Drugs (an international treaty later amended in 1972), cannabis was designated a Schedule I substance and participating countries are required to restrict production, manufacture, possession and distribution of marijuana except for medical and scientific purposes. The DEA regulates the cultivation of marijuana for research purposes through licensing requirements and establishing annual aggregate production quotas under the authority of the 1970 Controlled Substances Act (CSA), which implements the Single Convention. The DEA will now begin the process of reviewing applications in order to approve additional manufacturers and suppliers of cannabis for research purposes.

This represents a real opportunity for the industry. Historically, NIDA supply of research cannabis has not been consistent, and represents only a single, limited source of limited variety. With the introduction of new NIDA sources of cannabis, industry members should have more ready access to a greater variety of cannabis strains and products made from them. This should provide the industry with the supply necessary to allow for more sophisticated, focused research the likes of which the DEA and the FDA call for in the opinion documents.

More importantly, this move by the DEA to consider additional licenses for cultivation, shows movement on the part of at least one federal agency to make cannabis more available through additional licenses so the medical use of cannabis can be more widely researched.

However, the announcement also tells us that until the FDA changes its position on the merits of cannabis for medical use, other agencies such as the DEA are stymied. Although the DEA announcement does demonstrate a willingness to create a bigger platform for research, it cannot move any further until the FDA revises its position. In the meantime, the Department of Justice order to not engage in enforcement activities in those states where cannabis has been legalized remains in place. So, the tension created by the opposing positions of the states where cannabis has been legalized and the federal position on cannabis continues with a new twist opening the door to more research on the benefits of its use. The cannabis industry would be wise to continue its efforts to substantiate the medical benefits of cannabis through this new expanded research access, which may be the key to getting the FDA to revise its stance.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Related Topics
 
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions